Premium
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative
Author(s) -
Veitch Dallas P.,
Weiner Michael W.,
Aisen Paul S.,
Beckett Laurel A.,
Cairns Nigel J.,
Green Robert C.,
Harvey Danielle,
Jack Clifford R.,
Jagust William,
Morris John C.,
Petersen Ronald C.,
Saykin Andrew J.,
Shaw Leslie M.,
Toga Arthur W.,
Trojanowski John Q.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.08.005
Subject(s) - neuroimaging , alzheimer's disease neuroimaging initiative , clinical trial , disease , neuroscience , medicine , psychology , positron emission tomography , dementia , cognitive decline , oncology , pathology
The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI is a multisite, longitudinal, observational study that has collected many biomarkers since 2004. Recent publications highlight the multifactorial nature of late-onset AD. We discuss selected topics that provide insights into AD progression and outline how this knowledge may improve clinical trials.